EpiCept has reported a net loss of $1.13m, or $0.03 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.40m, or $0.08 per share, for the same period in 2011.
Loss from operations for the third quarter of 2012 was $1.08m compared to $4.37m operating loss in the previous year.
The company reported a net loss of $1.70m, or $0.06 per share, for the nine months ended 30 September 2012 compared to net loss of $12.20m, or $0.18 per share, for the same period in 2011.
Income from operations for the first nine months in 2012 was $288,000 compared to $11.38m loss from operations during the same period in 2011.
EpiCept interim president and CEO Robert Cook said, "During the third quarter we focused our attention on concluding an agreement with a merger partner that is interested in our products and in implementing a strategy to enable AmiKet to realize value for the Company's shareholders."
